1 - 50 of 56
Dr. Bagatell’s research focuses on improving therapies for children with neuroblastoma. She leads clinical research studies designed to critically evaluate current therapies for children with high-risk and relapsed disease, and is committed to conducting studies of new therapies for this population. She is currently pursuing research designed to evaluate biomarkers for response to targeted therapy in children with high-risk disease.
Dr. Bailey’s research centers on the development of learning health systems. This endeavor includes the creation of methods to share data across hospitals, recognize the clinical implications of information gathered from different sources, and provide support to clinicians to use this information more effectively.
Dr. Baldassano’s research focuses on children who have inflammatory bowel diseases, and he oversees a large team of researchers at CHOP working to translate discoveries in the laboratory into direct patient care for children. One promising area of current research involves investigating the intestinal microbiomes of children with inflammatory bowel diseases.
Dr. Balis's research focuses on the clinical pharmacology of anticancer drugs, new drug development, and clinical trial design and endpoints. He studies the pharmacokinetics and pharmacodynamics of anticancer drugs and has applied pharmacological principles to clinical trial design and clinical drug development. He is developing new biomarkers to serve as surrogate endpoints of drug toxicity or efficacy in clinical trials.
Dr. Barakat's research is focused on examining risk-and-resilience models to characterize disease management and health-related quality of life of children with chronic health conditions and their families. Another focus of investigation is translation of these models into evidence-based assessment (family psychosocial risk screening) as well as family-based, mHealth interventions to improve disease management and to support medical decision-making for youth with cancer and their families.
Dr. Barr's research focuses on transitions as important developmental epochs during which there are substantial changes in how infants/children/adolescents process information. He studies mechanisms of stress, pain, and recovery from damage to the nervous system from a developmental perspective.
Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
Dr. Bassing's research program focuses on the genetic, epigenetic, and biochemical mechanisms by which mammals develop their immune systems while suppressing autoimmunity and genomic aberrations that cause leukemia or lymphoma.
Dr. Bauer's academic and clinical career are focused on improving the care of children and adolescents with thyroid disease. He has extensive experience and knowledge of thyroid pathophysiology and tumorigenesis, and has been critical to the clinical success of the Children's Hospital of Philadelphia Thyroid Center.
Provides leadership in compliance and customer service for pre-award and non-financial post-award administration by assisting in developing and submitting proposals, serving as a resource for sponsor policies and regulations, and issuing and negotiating incoming and outgoing subawards and outgoing consulting agreements.
Dr. Bell, chief of the Division of General Pediatrics, has research expertise in areas including computerized clinical decision support to improve the quality of care; epidemiology, management and treatment of common pediatric infectious diseases; the use of primary care practice-based research networks for clinical research; and quality improvement through the use of clinical pathways.
Dr. Benton's research focuses primarily on pediatric mood and anxiety disorders, sickle cell disease and psychiatric conditions, HIV and psychiatric conditions, neuroimmunology and mood disorders, health services research, eating disorders, and ethnically diverse children.
Dr. Berg is a resuscitation scientist with extensive clinical and preclinical translational laboratory experience in the areas of cardiac arrest, VF, defibrillation, and personalized physiologic-directed CPR. He has substantial expertise in conducting multicenter observational and interventional trials.
Dr. Beslow works on the development of measurement and outcome prediction tools for pediatric hemorrhagic and ischemic stroke. She recently led a 61-center study carried out in 26 countries that evaluated the frequency of ischemic stroke among pediatric patients with SARS-CoV-2.
Dr. Bhatnagar's research aims to further the understanding of the neural basis of individual differences in response to stressful experiences. This includes identifying neural substrates that produce resiliency or vulnerability to the effects of stress and determining treatments to mitigate vulnerability and to promote resiliency through both preclinical and translational studies.
Dr. Bhoj's genetics research aims to discover new human disease genes, their mechanisms, and potential targeted therapies. In addition to ongoing gene discovery efforts, Dr. Bhoj focuses on three novel genes that lead to pediatric neurologic dysfunction: TBC1 domain-containing kinase, Histone 3.3 (H3F3A and H3F3B), and MAP4K4.
Dr. Blobel investigates the fundamental mechanisms involving transcription factors, chromatin regulators, and higher order chromatin. He is gearing his basic science discoveries towards genetic and epigenetic treatment modalities. In addition, Dr. Blobel is interested in mechanism of epigenetic memory.
Dr. Blum is the principal investigator for the national multi-site Developmental-Behavioral Pediatric Research Network (DBPNet). Recent studies in the network relate to the assessment and treatment of attention deficit/ hyperactivity disorder (ADHD) and of autism spectrum disorders (ASD).
Dr. Bonafide’s research focus is on developing, evaluating, and implementing interventions at the intersection of patient safety and technological innovation, and measuring the impacts of these interventions on children and families. His research includes methods drawn from clinical epidemiology, biostatistics, clinical informatics, systems engineering, and implementation science.
The cure rate for children with neuroblastoma is unacceptable, making it imperative that new therapies are developed. Dr. Bosse's laboratory is focused on discovering and developing new neuroblastoma cell surface immunotherapeutic targets. Along with his colleagues, Dr. Bosse's aim is to capitalize on the robust differential expression of these molecules with immune-based therapies and also define their mechanisms of overexpression and roles in tumorigenesis.
Dr. Broedur’s research interests focus on nanoparticle drug delivery and cancer predisposition. He is also interested in identifying novel cancer predisposition genes, and developing enhanced surveillance techniques to identify cancer early in predisposed individuals with the hope of improving outcome and reducing side effects.